Contrive Datum Insights has published "Ivd Market Size, Share & Industry Analysis, By Type (Reagents & Consumables, Instruments), Technique (Immunodiagnostics, Clinical Chemistry, Molecular Diagnostics, Hematology, Others), Setting (Laboratories, Point-of-care), Application (Infectious Diseases, Cardiology, Oncology, Gastroenterology, Others), End-user (Clinical Laboratories, Hospitals, Physicians' Offices, Others), and Regional Forecast, 2026-2034". The study sizes the global ivd market at USD 105 billion in 2025 and projects growth from USD 111.5 billion in 2026 to USD 188.5 billion by 2034, a compound annual growth rate of 6.79% across the forecast period.
In vitro diagnostic products are tests performed on blood, urine, tissue and other biological samples outside the human body to detect disease, monitor existing conditions and guide treatment decisions. The category spans instruments such as analyzers and readers alongside the reagents, assay kits, calibrators and consumables that run on them, covering techniques including immunoassay, clinical chemistry, molecular testing and hematology. Buyers include hospital and reference laboratories, physician offices, blood banks and public health agencies that run these tests as part of routine and specialty care.
Rising chronic and infectious disease testing volume
Rising chronic and infectious disease testing volume is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 6.79% a year, the type lines exposed to it move fastest: Reagents & Consumables compounds at 7.09%, taking its share of revenue from 68% to 69.8% and its value from USD 71.4 billion to USD 131.57 billion.
A more favourable outcome is possible. If faster adoption of molecular and point-of-care testing platforms alongside accelerated diagnostic infrastructure investment in emerging markets lifts volume growth above the base case, 2034 revenue reaches USD 210.3 billion instead of the USD 188.5 billion the base case carries.
On the downside, slower reimbursement reform, delayed regulatory approvals in emerging markets and sustained pricing pressure from group purchasing organizations hold volume and price growth below the base case, which would hold 2034 revenue to USD 171.1 billion. Instruments, which carries 32% of 2025 revenue, already grows at only 6.09% against the market's 6.79%, so the largest part of the base is also its slowest.
Reagents & Consumables Leads on Both Scale and Growth
Competition in the global ivd market runs along the type axis, not the regional one, and it concentrates on a single line. Reagents & Consumables is both the largest position, at 68% of 2025 revenue and USD 71.4 billion, and the fastest-growing, at 7.09%, taking it to 69.8% by 2034. A supplier without a position there is competing for a shrinking share of a market worth USD 105 billion.
Other Findings in the Study
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Technique | Immunodiagnostics | 36% · USD 37.8 billion | Molecular Diagnostics 10.19% |
| Setting | Laboratories | 78% · USD 81.9 billion | Point-of-care 9.17% |
| Application | Infectious Diseases | 30% · USD 31.5 billion | Oncology 9.4% |
| End-user | Clinical Laboratories | 45% · USD 47.25 billion | Physicians' Offices 8.43% |
- Based on regional analysis, North America led the global ivd market in 2025 with 38% of global revenue at USD 39.9 billion, reaching USD 64.09 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 27% in 2025 to 33% in 2034, with revenue growing from USD 28.35 billion to USD 62.21 billion.
- Middle East and Africa remains the smallest region throughout, at 4% of 2025 revenue and 4.5% by 2034.
- By type, the largest line in 2025 was Reagents & Consumables, at 68% of revenue and USD 71.4 billion.
- No type line grows faster than Reagents & Consumables, at a projected 7.09%.
- The United States is the largest single country market at USD 33.92 billion in 2025, 32.3% of global revenue.
Coverage runs to five axes, by type, and by technique, setting, application and end-user, with a revenue figure and a growth rate for every line in every year from 2020 to 2034, and bear, base and bull cases on the headline total at USD 171.1 billion and USD 210.3 billion by 2034. All five regions are broken out to country level, alongside the competitive landscape and the methodology behind each estimate. The study is delivered as a PDF, and a free sample can be requested.